UiPath Six Months Later: The Data Confirms the Crossroads

In September, I wrote that UiPath was "at a crossroads" — the investment case was "challenging until a clear, data-backed turnaround emerges." The concerns were specific: net new ARR had deteriorated sharply, GenAI was commoditizing basic automation, and management optimism wasn't matched by the numbers.

Six months and three quarterly filings later, the data is in. The crossroads assessment holds — but the picture is more nuanced than a simple "still broken" verdict.

The Numbers Haven't Inflected

The headline metric tells the story plainly. ARR growth was 11% year-over-year in each of the last three reported quarters — Q2, Q3, and Q4 of fiscal 2026. Not accelerating, not collapsing. Stuck.

Constant-currency revenue growth actually decelerated in Q4, coming in at 10% versus 14% the prior quarter. The reported number looked better — 14% — but that was inflated by a $16 million FX tailwind. Management led with the reported figure on the earnings call. The constant-currency reality was buried deeper.

Net retention rate continued its slow erosion: 108% to 107% to 107% reported, with constant-currency NRR at 106% in Q4. This matters because NRR measures whether existing customers are spending more over time. A declining NRR directly contradicts any narrative about AI-driven upsell momentum within the installed base.

FY2027 guidance tells the forward story: approximately 9% revenue growth, with a 1% headwind from the ongoing SaaS migration. ARR is guided to roughly $2.05 billion, implying about 10.8% growth — essentially flat to the current trajectory. Management's own numbers don't project an inflection.

The Genuine Bright Spots

Dismissing UiPath entirely would be intellectually lazy. There are real positive signals in the data, and they deserve honest assessment.

The enterprise deal momentum in Q4 was the strongest in two years. Customers with over $1 million in ARR jumped from 330 to 357, with deals exceeding $1 million up 50% year-over-year. That's not noise. These are large, deliberate enterprise commitments — the kind of deals that signal deep platform embedding.

RPO surged to $1.475 billion, up 19% year-over-year (14% on a constant-currency basis). RPO represents contracted future revenue, and a meaningful acceleration from the roughly 12% growth in prior quarters. This is the most positive leading indicator in the dataset.

Management disclosed that AI product ARR reached "nearly $200 million" in Q4, with 90% of $1M+ customers having adopted AI products. Customers using AI products spend approximately three times more than those without. These are genuine adoption metrics, not vaporware.

The company also reached full-year GAAP profitability for the first time in FY2026 and guided non-GAAP operating margin to approximately 23.6% for FY2027 — modest expansion from FY2026's 23%.

The Narrative Gap

Here's what makes UiPath difficult to assess: the gap between the forward-looking signals (enterprise deals, RPO acceleration, AI adoption metrics) and the backward-looking reality (ARR stuck at 11%, NRR eroding, revenue growth guided to decelerate).

Management is positioning aggressively around "agentic automation" — the idea that UiPath's platform becomes the orchestration layer for AI agents in the enterprise. The WorkFusion acquisition (financial crime compliance) and the Maestro orchestration product are concrete steps in this direction. The 30% long-term operating margin target (up from 20% previously) signals confidence in the platform's durability.

But the financial data says: stable, not inflecting. The enterprise deal momentum and RPO surge are genuine leading indicators worth monitoring — if they translate into ARR acceleration in the next two to three quarters, the thesis changes. Right now, they haven't.

The AI ARR disclosure itself is worth scrutinizing. "Nearly $200 million" was introduced at the most narratively convenient moment — after quarters of saying agentic contributions weren't yet material. The metric's definition is broad enough to include any product touching AI, and management constructed a penetration framework (90% of $1M+ customers) specifically to build an inflection story. Healthy skepticism is warranted until this metric shows up in the actual growth rate.

Where This Leaves the Thesis

The September assessment holds. UiPath is not irrelevant — the product has real enterprise adoption, the platform is genuinely evolving, and the company is profitable. But the growth inflection that would change the investment case hasn't materialized in the numbers.

The honest framing: UiPath is a ~$1.85 billion ARR business growing approximately 11%, with emerging signs of enterprise deal acceleration that haven't yet translated into topline growth. The "agentic automation" narrative is plausible but unproven at the financial level. The next two quarters will be diagnostic — if RPO acceleration and the $1M+ customer surge start showing up in ARR growth above 11%, the crossroads resolves upward. If ARR stays stuck while management continues to talk about agentic transformation, the gap between narrative and data widens.

I'll be watching the Q1 FY2027 filing closely. Until then, the data says: stable at the crossroads.